Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Single-Blind, Randomized, Multi-Center Study Comparing the Cypher Elite to the Cypher Bx Velocity Sirolimus-Eluting Stent Systems (ELITE)

Trial Profile

A Prospective, Single-Blind, Randomized, Multi-Center Study Comparing the Cypher Elite to the Cypher Bx Velocity Sirolimus-Eluting Stent Systems (ELITE)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Aug 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Acute coronary syndromes; Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms ELITE
  • Sponsors Cordis Corporation
  • Most Recent Events

    • 17 Dec 2013 Planned End Date changed from 1 Jun 2015 to 1 Sep 2014, according to ClinicalTrials.gov record.
    • 17 Mar 2009 Status changed from recruiting to active, no longer recruiting, according to a Cordis Corporation media release. Cordis plans to cease development of the Cypher Elite stent. Approximately 700 patients have been enrolled and will be followed for 5 years.
    • 07 Aug 2008 New trial record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top